Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more
Optipharm.CO.LTD (153710) - Net Assets
Latest net assets as of September 2025: ₩25.71 Billion KRW
Based on the latest financial reports, Optipharm.CO.LTD (153710) has net assets worth ₩25.71 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩42.32 Billion) and total liabilities (₩16.61 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩25.71 Billion |
| % of Total Assets | 60.75% |
| Annual Growth Rate | 22.82% |
| 5-Year Change | -19.08% |
| 10-Year Change | N/A |
| Growth Volatility | 83.76 |
Optipharm.CO.LTD - Net Assets Trend (2015–2024)
This chart illustrates how Optipharm.CO.LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Optipharm.CO.LTD (2015–2024)
The table below shows the annual net assets of Optipharm.CO.LTD from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩27.34 Billion | +8.71% |
| 2023-12-31 | ₩25.14 Billion | -13.33% |
| 2022-12-31 | ₩29.01 Billion | -6.28% |
| 2021-12-31 | ₩30.96 Billion | -8.36% |
| 2020-12-31 | ₩33.78 Billion | -5.14% |
| 2019-12-31 | ₩35.61 Billion | +0.46% |
| 2018-12-31 | ₩35.44 Billion | +177.16% |
| 2017-12-31 | ₩12.79 Billion | -5.27% |
| 2016-12-31 | ₩13.50 Billion | +214.30% |
| 2015-12-31 | ₩4.30 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Optipharm.CO.LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1669091037000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩7.33 Billion | 26.83% |
| Other Components | ₩47.84 Billion | 174.99% |
| Total Equity | ₩27.34 Billion | 100.00% |
Optipharm.CO.LTD Competitors by Market Cap
The table below lists competitors of Optipharm.CO.LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
S.Kijchai Enterprise Public Company Limited
BK:SKN
|
$30.16 Million |
|
Cambuci S.A
SA:CAMB3
|
$30.17 Million |
|
Integra Indocabinet Tbk PT
JK:WOOD
|
$30.18 Million |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
$30.19 Million |
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
$30.15 Million |
|
PPI Inc
KQ:062970
|
$30.15 Million |
|
SOTKAMO SILVER AB NAM.
F:VSO
|
$30.15 Million |
|
Crest Ventures Limited
NSE:CREST
|
$30.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Optipharm.CO.LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,144,342,540 to 27,335,443,690, a change of 2,191,101,150 (8.7%).
- Net loss of 2,356,570,950 reduced equity.
- Other factors increased equity by 4,547,672,100.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.36 Billion | -8.62% |
| Other Changes | ₩4.55 Billion | +16.64% |
| Total Change | ₩- | 8.71% |
Book Value vs Market Value Analysis
This analysis compares Optipharm.CO.LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.50x to 2.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1140.64 | ₩5130.00 | x |
| 2017-12-31 | ₩1080.50 | ₩5130.00 | x |
| 2018-12-31 | ₩2493.05 | ₩5130.00 | x |
| 2019-12-31 | ₩2476.67 | ₩5130.00 | x |
| 2020-12-31 | ₩2333.74 | ₩5130.00 | x |
| 2021-12-31 | ₩2121.75 | ₩5130.00 | x |
| 2022-12-31 | ₩1977.60 | ₩5130.00 | x |
| 2023-12-31 | ₩1714.00 | ₩5130.00 | x |
| 2024-12-31 | ₩1863.36 | ₩5130.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Optipharm.CO.LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.00%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.58x
- Recent ROE (-8.62%) is above the historical average (-11.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -51.43% | -19.34% | 0.66x | 4.05x | ₩-2.64 Billion |
| 2016 | -2.58% | -2.42% | 0.70x | 1.52x | ₩-1.70 Billion |
| 2017 | -12.25% | -11.31% | 0.70x | 1.55x | ₩-2.85 Billion |
| 2018 | -1.71% | -4.33% | 0.33x | 1.20x | ₩-4.15 Billion |
| 2019 | -1.84% | -4.80% | 0.33x | 1.17x | ₩-4.22 Billion |
| 2020 | -6.96% | -18.03% | 0.32x | 1.22x | ₩-5.73 Billion |
| 2021 | -9.95% | -21.60% | 0.35x | 1.33x | ₩-6.18 Billion |
| 2022 | -7.05% | -12.77% | 0.39x | 1.42x | ₩-4.95 Billion |
| 2023 | -9.69% | -14.03% | 0.44x | 1.56x | ₩-4.95 Billion |
| 2024 | -8.62% | -12.00% | 0.45x | 1.58x | ₩-5.09 Billion |
Industry Comparison
This section compares Optipharm.CO.LTD's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $38,041,802,661
- Average return on equity (ROE) among peers: -26.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Optipharm.CO.LTD (153710) | ₩25.71 Billion | -51.43% | 0.65x | $30.16 Million |
| JOONGANG DNM Co.Ltd (051980) | $21.11 Billion | -86.57% | 0.65x | $76.18 Million |
| GeneMatrix Inc (109820) | $10.04 Billion | -20.13% | 1.07x | $21.74 Million |
| Genoray Co. Ltd (122310) | $87.96 Billion | 15.80% | 0.21x | $24.43 Million |
| Green Cross Lab Cell Corporation (144510) | $47.72 Billion | 2.10% | 0.20x | $147.39 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $26.82 Million |
| U2Bio Co., Ltd. (221800) | $34.43 Billion | -8.25% | 0.31x | $84.67 Million |
| Gencurix Inc (229000) | $30.99 Billion | -111.87% | 0.78x | $21.52 Million |
| P&K Skin Research Center Co. Ltd (347740) | $74.24 Billion | 6.48% | 0.04x | $16.08 Million |
| Genesystem Co. Ltd. (363250) | $-12.70 Billion | 0.00% | 0.00x | $20.32 Million |